TY - JOUR
T1 - Risk of colorectal cancer among long-term cervical cancer survivors
AU - Rodriguez, Ana M.
AU - Kuo, Yong Fang
AU - Goodwin, James S.
N1 - Funding Information:
Sarah Toombs Smith, PhD, Science Editor and Assistant Professor in the Sealy Center on Aging, University of Texas Medical Branch at Galveston, provided editorial assistance in manuscript preparation. Dr. Toombs Smith received no compensation for her assistance apart from her employment at the institution where the study was conducted. Comparative Effectiveness Research on Cancer in Texas (CERCIT) is a statewide resource for outcomes and comparative effectiveness research funded by The Cancer Prevention Research Institute of Texas (CPRIT), RP101207.
PY - 2014/5
Y1 - 2014/5
N2 - Because advances in therapy have increased long-term survival for women with cervical cancer, it is important to study the risk of secondary primary malignancies in high-dose organ areas. From the 1973-2009 National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) program, we studied the risk of developing cancer of the colon and rectum in 64,507 cervical cancer patients over 35 years after initial radiation treatment. We also assessed change in risk over time. Kaplan-Meier estimator for survival curve and Cox proportional hazards models was used. More than half (52.6%) of the cervical cancer patients received radiation treatment. In the analyses adjusted for race/ethnicity, age, marital status, surgery status, stage and grade, the risk of colon cancer between those both with and without XRT diverged beginning at approximately 8 years. After 8 years, the hazard ratio for developing colon cancer was 2.00 (95% CI 1.43-2.80) for women with radiation versus those without radiation treatment. The risk of rectal cancer diverged after 15 years of follow-up (HR 4.04, 95% CI 2.08-7.86). After 35 years of follow-up, the absolute risk of developing colon cancer was 6.5% for those who received radiation versus 2.5% for those without, and 3.7 versus 0.8% for rectum. The risk of colon and rectum cancer over 20 years of follow-up after radiation remained the same across three eras (1973-1980, 1981-1990, and 1991-2000). Radiation-induced second cancers of the colon and rectum may occur 8 years after radiation treatment for cervical cancer.
AB - Because advances in therapy have increased long-term survival for women with cervical cancer, it is important to study the risk of secondary primary malignancies in high-dose organ areas. From the 1973-2009 National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) program, we studied the risk of developing cancer of the colon and rectum in 64,507 cervical cancer patients over 35 years after initial radiation treatment. We also assessed change in risk over time. Kaplan-Meier estimator for survival curve and Cox proportional hazards models was used. More than half (52.6%) of the cervical cancer patients received radiation treatment. In the analyses adjusted for race/ethnicity, age, marital status, surgery status, stage and grade, the risk of colon cancer between those both with and without XRT diverged beginning at approximately 8 years. After 8 years, the hazard ratio for developing colon cancer was 2.00 (95% CI 1.43-2.80) for women with radiation versus those without radiation treatment. The risk of rectal cancer diverged after 15 years of follow-up (HR 4.04, 95% CI 2.08-7.86). After 35 years of follow-up, the absolute risk of developing colon cancer was 6.5% for those who received radiation versus 2.5% for those without, and 3.7 versus 0.8% for rectum. The risk of colon and rectum cancer over 20 years of follow-up after radiation remained the same across three eras (1973-1980, 1981-1990, and 1991-2000). Radiation-induced second cancers of the colon and rectum may occur 8 years after radiation treatment for cervical cancer.
KW - Cervical cancer
KW - Colon cancer
KW - Radiotherapy
KW - Rectal cancer
KW - SEER
KW - Second primary cancer
UR - http://www.scopus.com/inward/record.url?scp=84897159518&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84897159518&partnerID=8YFLogxK
U2 - 10.1007/s12032-014-0943-2
DO - 10.1007/s12032-014-0943-2
M3 - Article
C2 - 24696219
AN - SCOPUS:84897159518
SN - 1357-0560
VL - 31
JO - Medical Oncology
JF - Medical Oncology
IS - 5
M1 - 943
ER -